Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Neuren Pharmaceuticals Limited ( (AU:NEU) ) is now available.
Neuren Pharmaceuticals Limited has provided an updated notice to the ASX regarding its ongoing on-market share buy-back program for its ordinary fully paid shares. The latest daily notification, dated 13 March 2026, confirms that a total of 72,500 shares had been repurchased prior to the previous trading day, with an additional 33,400 shares bought back on that day.
The update, which follows the initial buy-back notification lodged on 11 February 2026 and the prior update on 10 March 2026, reflects the company’s continued execution of its capital management strategy through on-market repurchases. This activity may signal management’s confidence in the company’s valuation and can have implications for shareholders through a reduced share count and potential enhancement of earnings per share over time.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$22.00 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited is an Australian biopharmaceutical company listed on the ASX under the code NEU. The company focuses on developing and commercialising pharmaceutical products, with its ordinary fully paid shares actively traded in the public market.
Average Trading Volume: 451,316
Technical Sentiment Signal: Sell
Current Market Cap: A$1.59B
See more data about NEU stock on TipRanks’ Stock Analysis page.